顺铂联合紫烷素或紫杉醇脂质体治疗乳腺癌的血液学毒性及不良反应对比

Hematological toxicity and adverse reactions of cisplatin combined with paclitaxel or paclitaxel liposomes in the treatment of breast cancer

目的:对比乳腺癌患者使用顺铂化疗联合紫烷素或紫杉醇脂质体的治疗的效果。方法:选取本院2021年6月至2023年3月收治的62例乳腺癌患者,采用随机数字表格法将患者分为两组(n=31)。对照组采用顺铂联合紫烷素治疗,观察组采用顺铂联合紫杉醇脂质体治疗。治疗21 d后观察对比两组的疗效,以全自动血液分析仪检测血小板(Platelet,PLT)、血红蛋白(Hemoglobin,HGB)、白细胞(White Blood Cell,WBC)水平,同时记录不良反应发生情况。结果:观察组的血红蛋白、白细胞减少血液毒性分级中0级占比均显著低于对照组(P<0.05)。观察组的皮疹、肝损伤、肌肉疼痛发生率低于对照组(P<0.05)观察组血清指标低于对照组(P<0.05)。结论:在顺铂用药基础上联合紫杉醇脂质体治疗的血液学毒性更低,且不良反应发生率更少。

Objective:To compare the effects of cisplatin chemotherapy combined with phypanein or paclitaxel liposomes in breast cancer patients.Methods:A total of 62 breast cancer patients admitted to our hospital from June 2021 to March 2023 were selected and divided into two groups(n=31)by random numerical table method.The control group was treated with cisplatin combined with phylpanka,and the observation group was treated with cisplatin combined with paclitaxel liposome.After 21 days of treatment,the efficacy of the two groups was observed and compared,and the levels of platelet(PLT),hemoglobin(HGB),white blood cell(WBC)were detected by an automatic hematology analyzer.And the adverse reactions were recorded.Results:The proportion of grade 0 in hemoglobin and leukopenia in the observation group was significantly lower than that in the control group(P<0.05).The incidences of rash,liver injury and muscle pain in the observation group were lower than those in the control group(P<0.05),and the serum indexes in the observation group were lower than those in the control group(P<0.05).Conclusion:The combination of paclitaxel liposomal therapy with cisplatin is associated with lower hematologic toxicity and less incidence of adverse reactions.